To investigate the mechanism of action of saroglitazar and curcumin in improving NAFLD, we detected the expression of PPARs, SREBP1, Nrf2, and ERK1/2 in the liver tissues of NAFLD model rats. This evidence concerns the gene MAPK3 and metabolic dysfunction-associated steatotic liver disease.